Trials / Completed
CompletedNCT05217927
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,415 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rimegepant 75mg daily dosing | Daily |
| DRUG | Rimegepant 75mg every other day dosing | Every other day |
| DRUG | Placebo comparator dosing | Placebo comparator |
Timeline
- Start date
- 2022-03-04
- Primary completion
- 2024-10-22
- Completion
- 2024-12-11
- First posted
- 2022-02-01
- Last updated
- 2025-12-16
- Results posted
- 2025-12-16
Locations
107 sites across 10 countries: United States, Austria, Canada, France, Germany, Italy, Poland, Spain, Sweden, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05217927. Inclusion in this directory is not an endorsement.